<DOC>
	<DOCNO>NCT00602680</DOCNO>
	<brief_summary>The primary objective study assess effect 3 dos SSR180711C cognitive performance patient mild Alzheimer 's Disease ( AD ) . Other objective assess safety/tolerability SSR180711C patient mild AD .</brief_summary>
	<brief_title>Effect Cognitive Performance Safety/Tolerability SSR180711C Mild Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Outpatients diagnosis mild AD Concomitant previous treatment acetylcholinesterase inhibitor and/or memantine Medical condition may interfere study History epileptic seizure Lens opacity Lack reliable caregiver The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Alzheimer</keyword>
	<keyword>cognitive</keyword>
</DOC>